NZ613779B2 - Materials for treating and preventing mucosa related disease - Google Patents
Materials for treating and preventing mucosa related disease Download PDFInfo
- Publication number
- NZ613779B2 NZ613779B2 NZ613779A NZ61377912A NZ613779B2 NZ 613779 B2 NZ613779 B2 NZ 613779B2 NZ 613779 A NZ613779 A NZ 613779A NZ 61377912 A NZ61377912 A NZ 61377912A NZ 613779 B2 NZ613779 B2 NZ 613779B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- million
- lmwha
- hmwha
- average
- average molecular
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 46
- 210000004877 mucosa Anatomy 0.000 title description 30
- 239000000463 material Substances 0.000 title description 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims abstract description 131
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 126
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 119
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 210000001533 Respiratory Mucosa Anatomy 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 229940079593 drugs Drugs 0.000 claims description 12
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 206010018987 Haemorrhage Diseases 0.000 claims description 3
- 230000003266 anti-allergic Effects 0.000 claims description 3
- 231100000319 bleeding Toxicity 0.000 claims description 3
- 230000000740 bleeding Effects 0.000 claims description 3
- 206010052613 Allergic bronchitis Diseases 0.000 claims description 2
- 230000001088 anti-asthma Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- 230000015556 catabolic process Effects 0.000 description 27
- 230000004059 degradation Effects 0.000 description 27
- 238000006731 degradation reaction Methods 0.000 description 27
- 210000001072 Colon Anatomy 0.000 description 26
- 102000001974 Hyaluronidase Human genes 0.000 description 24
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 24
- 229960002773 hyaluronidase Drugs 0.000 description 24
- 210000001519 tissues Anatomy 0.000 description 24
- 241000700159 Rattus Species 0.000 description 20
- 239000000843 powder Substances 0.000 description 17
- 238000005227 gel permeation chromatography Methods 0.000 description 14
- 230000014759 maintenance of location Effects 0.000 description 14
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 208000008469 Peptic Ulcer Diseases 0.000 description 11
- 206010009887 Colitis Diseases 0.000 description 10
- 230000002757 inflammatory Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000002784 Stomach Anatomy 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 206010006451 Bronchitis Diseases 0.000 description 8
- 208000004232 Enteritis Diseases 0.000 description 8
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 8
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 8
- 210000004400 Mucous Membrane Anatomy 0.000 description 8
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 8
- 230000002459 sustained Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004051 Gastric Juice Anatomy 0.000 description 7
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 7
- 206010068760 Ulcers Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000000172 allergic Effects 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 230000002496 gastric Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 6
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 6
- 210000000214 Mouth Anatomy 0.000 description 6
- 229940092253 Ovalbumin Drugs 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 201000009910 diseases by infectious agent Diseases 0.000 description 6
- 210000001508 Eye Anatomy 0.000 description 5
- KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 5
- 210000001331 Nose Anatomy 0.000 description 5
- 210000002379 Periodontal Ligament Anatomy 0.000 description 5
- 210000000664 Rectum Anatomy 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 230000004579 body weight change Effects 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 101700078950 CD44 Proteins 0.000 description 4
- 102100003735 CD44 Human genes 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 210000000981 Epithelium Anatomy 0.000 description 4
- 210000003238 Esophagus Anatomy 0.000 description 4
- 229940099552 Hyaluronan Drugs 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 210000004379 Membranes Anatomy 0.000 description 4
- 206010039083 Rhinitis Diseases 0.000 description 4
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000003146 cystitis Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-Trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
- 208000000718 Duodenal Ulcer Diseases 0.000 description 3
- 206010014013 Ear infection Diseases 0.000 description 3
- 229940095399 Enema Drugs 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 3
- 210000000088 Lip Anatomy 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 201000009870 Meckel's diverticulum Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007117 Oral Ulcer Diseases 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 208000005141 Otitis Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000001179 Synovial Fluid Anatomy 0.000 description 3
- 206010066969 Vitello-intestinal duct remnant Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 3
- -1 aluminum ion Chemical class 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 210000001198 Duodenum Anatomy 0.000 description 2
- 208000008754 Esophageal Disease Diseases 0.000 description 2
- 208000006881 Esophagitis Diseases 0.000 description 2
- 210000000744 Eyelids Anatomy 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 210000004392 Genitalia Anatomy 0.000 description 2
- 208000007565 Gingivitis Diseases 0.000 description 2
- 210000004907 Glands Anatomy 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 210000003097 Mucus Anatomy 0.000 description 2
- 210000003928 Nasal Cavity Anatomy 0.000 description 2
- 206010030201 Oesophageal ulcer Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000002435 Tendons Anatomy 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 208000000143 Urethritis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000002921 anti-spasmodic Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000002146 bilateral Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000003522 irritant Effects 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 201000008100 vaginitis Diseases 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholino)ethanesulfonic acid Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000007451 Chronic Bronchitis Diseases 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 210000000795 Conjunctiva Anatomy 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 210000000613 Ear Canal Anatomy 0.000 description 1
- 210000000883 Ear, External Anatomy 0.000 description 1
- 210000003027 Ear, Inner Anatomy 0.000 description 1
- 210000000959 Ear, Middle Anatomy 0.000 description 1
- 210000000111 Esophageal Sphincter, Lower Anatomy 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 210000004211 Gastric Acid Anatomy 0.000 description 1
- 210000001156 Gastric Mucosa Anatomy 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 206010074063 Ischaemic enteritis Diseases 0.000 description 1
- 206010023567 Labyrinthitis Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 229940031815 Mycocide Drugs 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010073310 Occupational exposure Diseases 0.000 description 1
- 206010033072 Otitis externa Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 229940020573 Plavix Drugs 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-M Sodium 2-anthraquinonesulfonate Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)[O-])=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-M 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000035507 absorption Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000001680 brushing Effects 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 1
- 230000001112 coagulant Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000001120 cytoprotect Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001050 lubricating Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000005261 otitis interna Diseases 0.000 description 1
- 201000000432 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Discloses the use of a hyaluronic acid mixture including a low average molecular weight hyaluronic acid (LMWHA) and a high average molecular weight hyaluronic acid (HMWHA), wherein the average molecular weight (Mw) of LMWHA is between 50 kilo Da and 1.5 million Da, and the average Mw of HMWHA is between 1.5 million Da and 5 million Da, but 1.5 million Da is excluded from both the average molecular weights of the LMWHA and of the HMWHA, wherein the average Mw of LMWHA is apart from the average Mw of HMWHA by at least 0.5 million Da, and a mixing ratio of the LMWHA to the HMWHA is in a range from 20:80 to 80:20 by weight; in the manufacture of a medicament for treating or preventing a respiratory mucosa related disorder or disease. ween 1.5 million Da and 5 million Da, but 1.5 million Da is excluded from both the average molecular weights of the LMWHA and of the HMWHA, wherein the average Mw of LMWHA is apart from the average Mw of HMWHA by at least 0.5 million Da, and a mixing ratio of the LMWHA to the HMWHA is in a range from 20:80 to 80:20 by weight; in the manufacture of a medicament for treating or preventing a respiratory mucosa related disorder or disease.
Description
MATERIALS FOR TREATING AND PREVENTING MUCOSA RELATED
DISEASE
The present invention generally relates to the use of a hyaluronic acid mixture
including a low average molecular weight hyaluronic acid (LMWHA) and a high average
molecular weight hyaluronic acid (HMWHA) in the manufacture of a medicament for
treating or preventing a respiratory mucosa related disorder or disease. Also described is a
composition of hyaluronic acids for treating and preventing mucosa related disorders or
diseases whereas the symptoms include ulceration, inflammation, allergic reaction and
bleeding.
Hyaluronic acid, also known as hyaluronan, hyaluronate and sodium hyaluronate, is
generally referred to as HA, which is a natural glycosaminoglycan macromelcule including
disaccharides composed of the alternative N-acetyl-D-glucosamine and D-glucuronic acid
linked via alternativeβ-1,3 andβ-1,4 glycosidic bonds. HA found in nature with a
molecular weight (Mw) between 50,000 Dalton (Da) and a few million Dalton usually has
high viscosity.
HA found in nature is the fluid with elasticity, filling between the cells and the
collagenous fibers and covering onto some epidermal tissues, mainly for protecting and
lubricating cells, for providing a platform for transporting the regulatory T cell, and also for
stabilizing collagen network and protecting collagen network from the mechanical damage.
HA is also a major lubricant in the tendon and the tendon sheath and on the surface of the
synovial membranedue to its lubricant feature and being a high shock absorber, and HA is
helpful for the tissue rheological mechanics, motion and the cell proliferation (referring to
Delpech, B. et al., 1997, Hyaluronan: fundamental principles and applications in cancer. J.
Intern. Med. 242, 41-48), and participates in the receptor interaction on the surface of some
cells, particularly to be the major receptor of CD44. CD44 is widely accepted as a marker of
the activated lymphocyte (referring to Teder P, et al., 2002, Resolution of lung inflammation
by CD44. Science, 296:155-158).
Recently, HA is applied in clinical treatment in the sodium salt form mainly in eye,
skin, orthopedics, surgery, arthritis, artery treatment and in cosmetic fields. The HA with
alkali metal ion, alkaline earth metal ion (for example the magnesium ion), aluminum ion,
ammonium ion, and salt form of the replacement of the ammonium ion can be the carrier for
assisting drug absorption (referring to Belgium Patent 904,547). The silver salt is used as
the mycocide and the gold salt is used for treating the rheumatoid arthritis among the heavy
metal salt of the HA (referring to WO 87/05517).
US Patent 5,888,986 discloses a method and related structure for using HA at an
effective concentration to treat cystitis, wherein the average Mw of the HA is more than
200,000 Da. There is only one species of HA with a certain Mw been applied in the
embodiment thereof. For example, HA with the average molecular weight of 650 kDa or
1,900 kDa is used to treat the cystitis; however, the single species of HA with the certain
average molecular weight cannot be used for both prompt treatment and sustained effect.
US patent application 2005/0080037 discloses the use of HA for treating acute and overuse
sprain and the reaction thereof, wherein the Mw of the HA is only between 900 KDa and
1200 KDa, and the single species of HA with the certain average Mw cannot perform both
prompt healing and prolonged action.
US Patent 7,354,910 discloses that the hyaluronic acid and hyaluronate with Mw
between 600 KDa and 1,200 KDa can be applied to treat inflammatory bowel disease (IBD).
However, hyaluronic acid and hyaluronate with merely one average molecular weight could
not cover both the immediate and sustained functions in the treating effect after being
injected into the patient, therefore, it is very inconvenient for patients clinically.
European patent 1369119 discloses the use of HA for treating autoimmune disease
with HA with Mw of 0.6 MDa to 3 MDa. However, the referenced patent only uses one
species of HA with a certain average molecular weight, lacking in both quick and long term
effects simultaneously.
The mucous membranes (or mucosae; singular mucosa) are linings of mostly
endodermal origin, covered in epithelium, and involved in absorption (gastrointestinal tract)
and secretion (gastrointestinal and respiratory tract). They line cavities that are exposed to
the external environment and internal organs and contiguous with the skin at several body
areas: at the nostrils, the mouth, the lips, the eyelids, the ears, the genital area, and the anus.
The sticky, thick fluid secreted by the mucous membranes and glands is termed mucus. The
term mucous membrane refers to where they are found in the body and not every mucous
membrane secretes mucus.
Conjunctivitis refers to inflammation of the conjunctiva (the outermost layer of the
eye and the inner surface of the eyelids). It is most commonly due to an infection or an
allergic reaction (referring to Richards A, May 2010. "Conjunctivitis". Pediatr Rev 31 (5):
196–208).
Otitis is a general term for inflammation or infection of the ear, in both humans and
other animals. It is subdivided into: Otitis externa that involves the outer ear and ear canal;
otitis media that involves the middle ear; otitis interna that involves the inner ear.
Allergic Rhinitis
Rhinitis is defined as inflammation of the nasal membranes and is characterized by
a symptom complex that consists of any combination of the following: sneezing, nasal
congestion, nasal itching, and rhinorrhea. The eyes, ears, sinuses, and throat can also be
involved. Allergic rhinitis is the most common cause of rhinitis and affects approximately
% of the population. While allergic rhinitis is not a life-threatening condition,
complications can occur and the condition can significantly impair quality of life, which
leads to a number of indirect costs (referring to Bousquet J et al. Allergic rhinitis
management pocket reference 2008. Allergy 2008 Aug; 63 (8):990-996). US patent
application 20050107330 discloses a pharmaceutical composition for curative topical
treatment of rhinitis comprising at least one acidic glycosaminoglycan. However, this
invention also contains at least one sympathomimetic suitable for topical application and
having vasoconstrictor action or detumescent action on the mucous membrane or its
physiologically acceptable salts or derivatives. Therefore, it did not disclose or teach
combining HAs with two different average molecular weights.
Mouth
Oral mucosa is the mucous membrane epithelium of the mouth. An oral ulcer is an
open sore inside the mouth, or, in rare cases, a break in the mucous membrane or the
epithelium on the lips or surrounding the mouth. The types of ulcers are diverse, with a
multitude of associated causes including: physical abrasion, acidic fruit, infection, other
medical conditions, medications, and cancerous and nonspecific processes. Once formed,
the ulcer may be maintained by inflammation and/or secondary infection. Two common
types are aphthous ulcers ("canker sores") and cold sores (fever blisters, oral herpes). Cold
sores around the lip are caused by viruses (referring to J.M. Casiglia, et al., October 2006.
"Aphthous stomatitis". Emedecine (website)).
Bronchitis
Bronchitis is inflammation of the mucous membranes of the bronchi, the airways
that carry airflow from the trachea into the lungs. Bronchitis can be divided into two
categories, acute and chronic, each of which has unique etiologies, pathologies, and
therapies. Acute bronchitis often occurs during the course of an acute viral illness such as
the common cold or influenza. Chronic bronchitis most often develops due to recurrent
injury to the airways caused by inhaled irritants. Cigarette smoking is the most common
cause, followed by air pollution and occupational exposure to irritants (Cohen, Jonathan and
William Powderly. Infectious Diseases. 2nd ed. Mosby (Elsevier), 2004. "Chapter 33:
Bronchitis, Bronchiectasis, and Cystic Fibrosis"). US patent application 20030171332
discloses a method of treating respiratory conditions by a polysaccharide capable of binding
CD44. However, only one single species of HA can be involved.
Gastrointestinal Mucosa
The mucosa is the innermost layer of the gastrointestinal wall that is surrounding
the lumen, or open space within the tube. This layer comes in direct contact with food bolus,
and is responsible for absorption, digestion, and secretion which are the important processes
in digestion.
The mucosae are highly specialized in each organ of the gastrointestinal tract, facing
a low pH in the stomach, absorbing a multitude of different substances in the small intestine,
and also absorbing specific quantities of water in the large intestine. Reflecting the varying
needs of these organs, the structure of the mucosa can consist of invaginations of secretory
glands (e.g., gastric pits), or it can be folded in order to increase surface area.
The gastrointestinal mucosa forms a barrier between the body and a lumenal
environment which not only contains nutrients, but is laden with potentially hostile
microorganisms and toxins. The challenge is to allow efficient transport of nutrients across
the epithelium while rigorously excluding passage of harmful molecules and organisms into
the animal. The exclusionary properties of the gastric and intestinal mucosa are referred to
as the "gastrointestinal barrier". In general, toxins and microorganisms that are able to
breach the single layer of epithelial cells have unimpeded access to the systemic circulation.
Gastroesophageal reflux disease (GERD) is chronic symptoms or mucosal damage
caused by gastric acid coming up from the stomach into the esophagus. A typical symptom
is heartburn. GERD is usually caused by changes in the barrier between the stomach and the
esophagus, including abnormal relaxation of the lower esophageal sphincter, which
normally holds the top of the stomach closed; impaired expulsion of gastric reflux from the
esophagus, or a hiatal hernia. These changes may be permanent or temporary("transient")
(referring to DeVault KR, 1999. "Updated guidelines for the diagnosis and treatment of
gastroesophageal reflux disease. The Practice Parameters Committee of the American
College of Gastroenterology". Am J Gastroenterol 94 (6): 1434–42).
Peptic ulcer
As generally known a peptic ulcer and also known as PUD or peptic ulcer disease,
peptic ulcer is an ulcer (defined as mucosal erosions equal to or greater than 0.5 cm) of an
area of the gastrointestinal tract that is usually acidic and thus causes extreme pain. Almost
70-90% of ulcers are associated with Helicobacter pylori, a spiral-shaped bacterium that
lives in the acidic environment of the stomach. Ulcers can also be caused or worsened by
drugs such as aspirin, Plavix (clopidogrel), ibuprofen, and other NSAIDs (non-steroid
anti-inflammatory drugs).
Contrary to general belief, peptic ulcers arise more in the duodenum (first part of
the small intestine, just after the stomach) rather than in the stomach. About 4% of stomach
ulcers are caused by a malignant tumor, so multiple biopsies are needed to exclude cancer.
Duodenal ulcers are generally benign. The classification of peptic ulcer by region or
location includes: Stomach (called gastric ulcer); Duodenum (called duodenal ulcer);
Esophagus (called esophageal ulcer); Meckel's Diverticulum (called Meckel's Diverticulum
ulcer).
The above embodiments all stand for mucosa related disorder or disease but are not
limited to aforementioned. The disclosed disorders or diseases may be treated by different
drugs or therapies so far. However, such treatments are mostly achieved by drug with
complicated composition through highly specialized preparation processes and not by a
simple and safe treatment. No prior art except the inventor of the present invention taught or
predicted combining two species of HA with two different average molecular weights
(LMWHA and HMWHA) separated by 1.5 million Da, which means a person skilled in the
art cannot induce the concept of the utility of the mixture by combining any other prior arts.
Described herein is a method of treating mucosa related disorder by administering
to a subject in need thereof a therapeutically effective amount of a mixture of hyaluronic
acid comprising at least two hyaluronic acid compositions to mitigate or obviate the
aforementioned problems.
Also described is use of the biological activity of at least two species of hyaluronic
acids with different average molecular weights or the pharmaceutically acceptable salt
thereof to treat mucosa related disorder or disease. The low average molecular weight
hyaluronic acid (LMWHA) and the high average molecular weight hyaluronic acid
(HMWHA) have different viscidity, function of insulation and degradation rates. The
hyaluronic acid with an average Mw lower than 1.5 million Da is categorized as LMWHA,
and the hyaluronic acid with an average Mw higher than 1.5 million Da is categorized as
HMWHA. Thus, mixture of LMWHA and HMWHA can form a desired composition,
wherein the LMWHA can rapidly cover the inflammatory surface to treat and prevent
mucosa related disorder or disease (for example, conjunctivitis, otitis, allergic rhinitis,
gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis,
gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), irritable bowel syndrome
(IBS), urethritis, cystitis or vaginitis), and the HMWHA can prolong the degradation in
order to achieve a longer effective period. Thus, a faster treatment and a sustained release
effect may be achieved; and/or the public may be provided with a useful choice.
Accordingly, the present invention relates to the use of a hyaluronic acid mixture
including a low average molecular weight hyaluronic acid (LMWHA) and a high average
molecular weight hyaluronic acid (HMWHA), wherein the average molecular weight (Mw)
of LMWHA is between 50 kilo Da and 1.5 million Da, and the average Mw of HMWHA is
between 1.5 million Da and 5 million Da, but 1.5 million Da is excluded from both the
average molecular weights of the LMWHA and of the HMWHA, wherein the average Mw
of LMWHA is apart from the average Mw of HMWHA by at least 0.5 million Da, and a
mixing ratio of the LMWHA to the HMWHA is in a range from 20:80 to 80:20 by weight;
in the manufacture of a medicament for treating or preventing a respiratory mucosa related
disorder or disease.
Certain statements that appear below are broader than what appears in the
statements of the invention above. These statements are provided in the interests of
providing the reader with a better understanding of the invention and its practice. The reader
is directed to the accompanying claim set which defines the scope of the invention.
Also described is a composition for use on a mammal or a human in treating or
preventing a mucosa related disorder or disease comprising:
a therapeutically effective amount of a hyaluronic acid mixture (HA mixture)
including a low average molecular weight hyaluronic acid (LMWHA) and a high average
molecular weight hyaluronic acid (HMWHA), wherein the average molecular weight (Mw)
of LMWHA is between 50 kilo Da and 1.5 million Da, and the average Mw of HMWHA is
between 1.5 million Da and 5 million Da, wherein the average molecular weight of
LMWHA is apart from the average molecular weight HMWHA by at least 0.5 million Da,
and a mixing ratio of the LMWHA to the HMWHA is in a range from 20:80 to 80:20 by
weight.
Other objectives, advantages and novel features of the invention will become more
apparent from the following detailed description when taken in conjunction with the
accompanying drawings.
The scenario of the present invention is introduced in the prologue of degradation of
hyaluronic acid (HA) by hyaluronidase (HAase). The linear (LMWHA) or globular HA
(HMWHA) is degraded into small fragments whereas the globular HA can compensate for
the linear one to contribute to the treatment effect so as to prolong the action time. It has
been well known that HAase activity can be used as a marker of inflammation as briefed
below. Accordingly, combination of low average and high average molecular weight (Mw)
HAs is utilized to proceed with treatment effect accompanied by long-term action.
Therefore, the loss of shorter HA can be sustained supplied result in continues wound
healing or providing a soft barrier to isolate a protected tissue from damage. Hereinafter will
be the detail description of the scenario.
The composition as described herein used to treat and prevent mucosa related
disorder or disease comprises a therapeutically effective amount of a HA mixture including
a low average molecular weight hyaluronic acid (LMWHA) and a high average molecular
weight hyaluronic acid (HMWHA). Low average Mw HA is based on its repeated
disaccharide units to form a linear structure (Fig. 1); however, in the high average Mw HA,
by the reaction of hyalauronic acid with an amine, it is believed that the carboxylic groups
of the linear hyaluronic acid macromolecule react with the di/tri/poly amines to form an
amide linkage and form an inter- or intra- molecular bridge. Due to this reaction, the starting
coiled hyaluronic acid structure is transformed into a globular spherical nanoparticle (U.S.
Patent No.7,879,818). Different molecular weights have different rheology, adhesion,
functions of tissue scaffold and degradation in the solution, and therefore, the hyaluronic
acid mixture can balance the drug effect and the degradation rate in order to treat and to
prevent mucosa related disorder or disease, as well as to achieve a proper and prolonged
treatment effect.
Tranchepain F et al. disclose that HA has different biological functions according to
its molar mass. Physicochemically, studies of native HA hydrolysis catalyzed by bovine
testicular HAase have suggested that kinetic parameters depend on HA chain length. HA
hydrolysis catalyzed by HAase was used in a new procedure to obtain HA fragments of
different molar masses (Tranchepain F et al., A complete set of hyaluronan fragments
obtained from hydrolysis catalyzed by hyaluronidase: Application to studies of hyaluronan
mass distribution by simple HPLC devices. Anal Biochem. 2006 Jan 15; 348(2): 232-42.).
Similarly, the same research group also discloses that HA has various biological functions
that are strongly dependent on its chain length. HA hydrolysis catalyzed by HAase is
believed to be involved in the control of the balance between longer and shorter HA chains.
Shorter HA chains seem to be too short to form a stable complex and longer HA chains also
encounter difficulties in forming a complex, probably because of steric hindrance.
Several reports describe that HAase is involved in inflammation. Synovial fluid (SF)
HAase activity could be used as a marker of synovial inflammation (Nagaya H et al.,
Examination of synovial fluid and serum HAase activity as a joint marker in rheumatoid
arthritis and osteoarthritis patients. Ann Rheum Dis., 1999, 58(3): 186-8). HA is a major
component of the extracellular matrix of periodontal ligament (PDL) contributing to the
structural and functional integrity. HA contributes to the buffering effect of the PDL during
chewing, and they are also important in inflammation and wound healing. The study
suggests that PDL fibroblast expresses HAase and generates HAase activity essential for
extracellular HA metabolism under physiological and inflammatory conditions (Ohno S et
al., Expression and activity of hyaluronidase in human periodontal ligament fibroblasts. J
Periodontol., 2002, , 73(11): 1331-7). Short HA fragments catalyzed by HAase are involved
in inflammation processes and angiogenesis, whereas native HA is not(Tranchepain F et
al.,Supra).
As described herein, HA with an average molecular weight lower than 1.5 million
Da is categorized as LMWHA, the preferred range of the average molecular weight is
between 50 kilo Da and 1.5 million Da, the more preferred range of the average molecular
weight is between 0.1 million and 1.5 million Da, and the most preferred range of the
average molecular weight is between 0.1 million and 0.5 million Da. HA with an average
molecular weight higher than 1.5 million Da is categorized as HMWHA, the preferred range
of the average molecular weight is between 1.5 million and 5 million Da, and the most
preferred range of the average molecular weight is between 1.5 million and 2.5 million Da.
When the composition containing a mixture of LMWHA and HMWHA is administered to a
subject in need thereof, the LMWHA promptly covers the inflammatory portion to treat and
prevent mucosa related disorder or disease, meanwhile theHMWHA extends the treatment
effect of the LMWHA. Thus, treatment is promptly achieved and release effect is sustained.
The general chemical structure of the HA may be illustrated as in Fig. 1.
The species of HA is not only being shown as Mw but also as intrinsic viscosity (η)
which is directly related to the Mw of a polymer through the Mark-Houwink-Sakurada
(MHS) equation: [η] = KMα. For hyaluronic acid, K is 0.00057 and the exponent α is
0.75 at the following conditions: 0.15 M NaCl in phosphate buffer, pH 7.5, 20°C (“Standard
Guide for Characterization and Testing of Hyaluronan as Starting Materials Intended for
Use in Biomedical and Tissue Engineered Medical Product Applications”, ASTM
Designation: F 2347-03).
The present invention provides results showing that high average Mw HA can
compensate for low average Mw HA even under action of HAase (Fig. 2) or artificial gastric
juice (Fig. 3). The results indicate that HA can be replenished in the situation where HAase
exists or in the gastrointestinal environment to keep a long-term effect. The retention time
was obviously increased with the increased degradation of all three HAs under HAase (Fig.
2). The retention time was slowly increased with the increased degradation of all three HAs
under acid environment (Fig. 3). The simulated physiological situations were used to
proceed in experimental parameters, but true physiological environments are more
complicated that may cause slightly different result. However, the trend of HA degradation
will not be changed owing to its natural molecular characteristic that high average Mw HA
can compensate for low average Mw HA.
Another preferred embodiment of the composition as described herein includes, but
not limited to, a 1: 1 (w/w) mixture of LMWHA and HMWHA by weight in a salt form of
HA, and a more preferred embodiment of the ratio of LMWHA to HMWHA may be
adjusted depending on the clinical purpose to be between 20:80 and 80:20 by weight. The
HA mixture with a higher ratio of LMWHA to HMWHA can be more helpful in speeding up
the treatment; on the contrary, a higher ratio of HMWHA to LMWHA can provide a longer
degradation time to prolong the overall treatment effect.
The term mucosa used herein includes, but not limited to, the mucosa of an eye, the
mucosa of an ear, the mucosa of a nose, the mucosa of a mouth, the mucosa of a respiratory
tract, the mucosa of a gastrointestinal tract, the mucosa of a urinary tract and the mucosa of
a genital tract, whereas mucosa related disorder or disease comprises symptoms of
ulceration, inflammatory, allergic reaction or bleeding. The preferred embodiment of the
mucosa related disorder or disease includes, but not limited to, conjunctivitis, otitis, allergic
rhinitis, gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (GERD),
esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), irritable
bowel syndrome (IBS), urethritis, cystitis and vaginitis. The more preferred embodiment of
enteritis includes, but not limited to, acute enteritis, chronic enteritis, infectious enteritis,
ischemic enteritis, radioenteritis and drug induced enteritis. The more preferred embodiment
of peptic ulcer includes, but not limited to, gastric ulcer, duodenal ulcer, esophageal ulcer
and Meckel's Diverticulum ulcer. The more preferred embodiment of IBD includes, but not
limited to, Crohn's disease and ulcerative colitis. The more preferred embodiment of IBS
includes, but not limited to, coeliac disease, fructose malabsorption, mild infections,
parasitic infections like giardiasis, functional chronic constipation and chronic functional
abdominal pain.
The result of the present invention shows that the HAs with the same average Mw
were absorbed in the injured colon tissues obviously higher than in the normal colon tissues
(P<0.01, Fig. 4). Comparing the differences among HAs of three average molecular weights
absorbed in the injured colon tissues, the fluorescent index of absorption of 350 KDa HA by
the injured colon tissues was obviously higher than the HAs of the other two average
molecular weights (2000 kDa and 1000 kDa). Further, the fluorescent index of absorption of
1 MDa HA by even normal or injured colon tissues was higher than 2000 kDa HA. This
result explains fast dispersed and covered effect of low Mw HA which supplies instant
wound healing and protection of the tissue from being injured further. Combining the
aforementioned data, described is a method of fast and constant treatment or prevention of
mucosa related disorder or disease.
Another preferred embodiment of the composition as described herein further
includes an excipient to formulate an administrating dosage form for eye, ear, oral, nose,
respiratory tract, gastrointestinal tract or topical use. The more preferred embodiment of the
administrating dosage form for oral use is selected from the group consisting of solid dosage
form, solution including, but not limited to suspension, tablet including, but not limited to
controlled-release tablet, and capsule including, but not limited to enteric-coated capsule.
The most preferred embodiment of the solid dosage form is orally administered at a dose of
between 50 mg and 1000 mg per day. The more preferred embodiment of the administrating
dosage form for gastrointestinal tract use is selected from the group consisting of solid
dosage form, perfusion, enema, suppository, and solution including, but not limited to
suspension. The more preferred embodiment of the administrating dosage form for topical
use is selected from the group consisting of perfusion, enema, suppository, spray, inhalation,
and drop.
The preferred embodiment of treating allergic rhinitis or bronchitis can be carried
out by administrating the composition as described as an adjuvant conjunctively used with a
drug of antihistamine, antiallergics, anticongestives, steroid or antiasthma to a subject in
need thereof. The preferred embodiment of treating enteritis can be carried out by
administering the mixture as described as an adjuvant conjunctively used with a drug of
antibiotic or antispasmodic to a subject in need thereof. The preferred embodiment of
treating peptic ulcer can be carried out by administering the mixture as described as an
adjuvant conjunctively used with a drug of coagulant, antibiotics, antacid, H2 blocker,
potassium hydrogen ion pump blocker (PPI), cytoprotectives or mucosa protector to a
subject in need thereof. The preferred embodiment of treating IBD can be carried out by
administering the mixture as described as an adjuvant conjunctively used with a drug of
steroid, immunosuppressive agent, antibiotic, 5-ASA (5-aminosalicylic acid) and derivatives,
or anti-inflammatory to a subject in need thereof.
Also described is IBD treated by HAs of different weight mixing ratios, which are
indicated by average weight changes. In Figs. 5A and 5B, group A represents a mixture of
HMWHA and LMWHA in a mixing ratio of 8:2 by weight, whereas group B represents a
mixture of HMWHA and LMWHA in a mixing ratio of 1:1 by weight. Group C represents a
control group that HAs were replaced by PBS buffer. Although the statistic significance is
only presented in days 5 and 6, the importance of the figure is in the trend of each group
through day 1 to day 14. With days going, the trend shows that groups A and B both had
relief effect on colitis, which also belongs to IBD. In average weight changes between
control (group C) and HAs (groups A and B), treatment effect of colitis causes the average
body weights of group by administered HAs were kept being higher than control group
during the whole experimental period even till test day 14 (Fig. 5A). Interestingly, the trend
also indicates that group B generally has a better treatment effect than that of group A,
which means higher proportion of LMWHA has more efficient treating effect. This can
support the technical feature of the present invention that uses HMWHA to compensate for
LMWHA in order to prolong the effect.
The present invention takes advantage of nose rubbing as an easy index to indicate
allergic symptom and the result of amelioration when the number of nose rubbing decreased.
The result shows significant difference on day 28 (D28) between group control (only
administered PBS) and group HA, which means allergic symptom has been successfully
induced (Fig. 6). Though the result on day 30 (D30) does not have statistically significant
difference, the allergic symptom still has obviously reduction between group control and
group HA. Therefore, the trend of alleviating the allergic symptom has been highly proved
by the result of administrating the HA mixture as described (Fig. 6).
The result may be slightly different in various experiments; however, the trend
under overview of the present invention can be deduced to that the composition as described
has ability to ameliorate mucosa related disease or disorder including allergic symptoms. In
order to properly show the results, the present invention is proved by several related
experiments with shorter test time; however, in actual application of the target of the present
invention on mammals there would be a longer term than in the experiments. Therefore,
based on theories and the results of the present invention, the HMWHA as described shall
be sufficient to support a long term assisting and/or compensating for the instant treatment
effect of the LMWHA inside the body.
The preferred embodiment of treating IBS can be carried out by administering the
mixture as described as an adjuvant conjunctively used with a drug of antiallergic,
antispasmodic, antidiarrheal, neurolytic, tranquilizer, narcotic analgesic, antidepressant or
serotonin antagonist to a subject in need thereof.
In the preferred embodiment of oral formulation (for example enteric coated tablet),
the enteric coating provides more resistance dissolution and digestion in the stomach, and
after reaching the intestine and colon, the enteric coating will be dissolved and the HA
mixture herein will be released to form a protection membrane at the inflammatory colon
(the region uprising ascending or Transverse colon) in order to accelerate healing of the
inflammatory region and also to prolong the treatment effect by long degradation rate.
In the preferred embodiment of suppository formulation, the suppository containing
HA mixture herein may be inserted into the anus and the mixture will dissolve in the rectum
and spread to other regions of the colon (for example the descending region) to form a
protection membrane at the inflammatory colon in order to accelerate healing of the
inflammatory region and also achieve sustained release effect.
In the preferred embodiment of perfusion formulation (for example enema), the HA
mixture herein is the major active ingredient mixed with the excipient (for example
phosphate buffered saline (PBS solution or suspension formulation)) directly used or in a
soft tube to inject the above HA mixture into the colon. The HA mixture will be charged
into the colon and spread to other regions of the colon (for example the descending region)
to form a protection membrane at the inflammatory colon in order to accelerate the healing
of the inflamed region and also achieve sustained release effect.
The more preferred embodiment of the subject being treated by the mixture used
herein is mammal. The most preferred embodiment of the subject is human.
According to the above description, at least two species of pharmaceutically
acceptable salt of the hyaluronic acids with different molecular weights are mixed to rapidly
cover the wound or inflammatory surface and shorten the treatment period and prolong the
degradation in order to prolong the coverage period. Thus, a faster treatment and a sustained
release effect are achieved. The present invention provides an easier and safe way to treat
aforementioned disorders or diseases and also a less costly way to assist related patients by
supplying them with a better choice.
While the invention has been described in conjunction with a specific best mode, it
is to be understood that many alternatives, modifications, and variations will be apparent to
those skilled in the art in light of the foregoing description. Accordingly, it is intended to
embrace all such alternatives, modifications, and variations which fall within the spirit and
scope of the included claims. All matters set forth herein or shown in the accompanying
drawings are to be interpreted in an illustrative and non-limiting sense.
Fig. 1 shows the general chemical structure of hyaluronic acid;
Fig. 2 shows the retention time of HAs by GPC diagram, wherein the vertical axis
represents the retention time in GPC, and the horizontal axis represents the degradation time
of HA in a solution containing HAase;
Fig. 3 shows the retention time of HAs by GPC diagram, wherein the vertical axis
represents the retention time in GPC, and the horizontal axis represents the degradation time
of HA in artificial gastric juice;
Fig. 4 shows the affinity of HAs by fluorescent index in normal and injured colon
tissues;
Fig. 5A shows effects of two categories of HAs on treating colitis indicated by
average body weight of rats through test days 1 to 9;
Fig. 5B shows effects of two categories of HAs on treating colitis indicated by
average body weight of rats through test days 1 to 14; and
Fig. 6 shows the effect of HA sample on nasal rubbing induced by ovalbumin (10
μg/10 μl/nostril) in rats, demonstrating that significant difference between group HA and
group control on day 28 (D28) was observed (*p<0.05).
Example 1: The degradation of HA in 1U/ml HAase
Procedure:
1. 0.25 g High molecule weight sodium hyaluronate powder (HHA; Mw: 2 MDa;
Freda) and 0.25 g low molecule weight sodium hyaluronate powder (LHA; Mw: 0.35 MDa;
Freda) were added into 50 ml PBS buffer (Phosphate buffered saline) respectively to form
0.5 % solution, and then stirred for 6 hours until the powder was totally dissolved.
2. 0.05 g LHA powder and 0.2 g HHA powder (ratio 2:8; medium molecular weight
sodium hyaluronate powder, MHA) were added into 50 ml PBS buffer, and then stirred for 6
hours until the powder was totally dissolved.
3. Mobile phase solution of GPC (Gel permeation chromatography) system was
prepared by: (1) adding 35.49 g Na HPO powder into 450 ml deionized distilled water (dd
water) and stirred for 30 minutes in room temperature to form 0.5 M Na HPO solution; and
(2) adding 18 g NaH PO powder into 250 ml dd water and stirred for 30 minutes in room
temperature to form 0.5 M NaH PO solution.
4. 1U/ml HAase was prepared by dissolving HAase powder into PBS buffer in 4℃.
. 2 ml HA sample, 1 ml 10U/ml HAase and 7 ml PBS buffer were mixed for 3
minutes by vortex in 15 ml glass tube.
6. The tube was shaken by 50 rpm in water bath. 1 ml solution was taken after the
15, 30, 45, 60, 75, 90, 105, 120 minutes and then supplied with 1 ml HAase each time.
Every 1 ml solution was filtered through 0.45 μm filter. 20μl solution was injected into
GPC system and then the diagram was recorded.
7. The situation of GPC system were (1) column: 2x GMPWxl (TSK-gel); (2)
mobile phase flow rate : 1 ml/min; (3) temperature : 30°C.
8. All values in the table were expressed as means of n observations. The
histological index was analyzed by Student’s t-test.
Result:
Fig. 2 shows the retention time of HAs by GPC diagram. The vertical axis
represents the retention time in GPC, the horizontal axis represents the degradation time of
HA in solution containing HAase. The horizontal dotted lines from up to down represent the
retention time of 2 MDa, 1MDa, 350 KDa and 17 KDa HAs, respectively. The retention
time was obviously increased followed with the increased degradation of all three HAs.
After 15 minutes of degradation, the average Mw of HHA and MHA were degraded to about
1 MDa. After 37 minutes of degradation, the average Mw of HHA and MHA were degraded
to about 350 KDa. After 90 minutes of degradation, the average molecular weights of HHA,
MHA and LHA were degraded such that no obvious difference exists among the average
molecular weights, which were all larger than 17 KDa.
Example 2: The degradation of HA in 0.1 N HCl
Procedure:
1. LHA, MHA and HHA were prepared as the same as Example 1.
2. Mobile phase solution of GPC system was prepared as the same as Example 1.
3. Artificial gastric juice (0.1 N HCl) was prepared by mixing 5.72 ml 17.5 N HCl
and 90 ml dd water and stirred for 10 minutes as a stocking solution.
4. 2 ml of HHA, MHA and LHA were mixed with 8 ml artificial gastric juice,
respectively in a 15 ml glass tube and by vortex for 3 minutes.
. The tube was shaken by 50 rpm in 37℃ water bath. 1 ml solution was taken after
the 6, 12, 24, 48 hours and then supplied with 1 ml artificial gastric juice each time. Every 1
ml solution was filtered through 0.45 μm filter. 20 μl solution was injected into GPC
system and then the diagram was recorded.
6. All values in the table were expressed as means of n observations. The
histological index was analyzed by Student’s t-test.
Result:
Fig. 3 shows the retention time of HAs in GPC diagram. The vertical axis represents
the retention time in GPC, the horizontal axis represents the degradation time of HA in
artificial gastric juice. The horizontal dotted lines from up to down represent the retention
time of 2 MDa, 1MDa, 350 KDa and 17 KDa HAs, respectively. The retention time was
slowly increased followed by the increased degradation of all three HAs. After 7 hours of
degradation, the average molecular weights of HHA and MHA were degraded to about 1
MDa. After 31 hours of degradation, the average Mw of MHA was degraded to about 350
KDa. After 35 hours of degradation, the average Mw of HHA was degraded to about 350
KDa. The aforementioned data all indicate that HA was slowly degraded in the artificial
gastric juice whereas the average molecular weights of HHA and MHA were larger than 1
MDa after 6 hours of degradation, and the average molecular weights of HHA and MHA
were larger than 350 KDa after 24 hours of degradation.
Example 3: The adhesion of HA in colon tissue (IVIS image system-vision 3)
Procedure:
1. LHA and HHA were prepared as the same as Example 1. MHA (MHA; Mw: 1
MDa; Freda) were added into 50 ml PBS buffer, and then stirred for 6 hours until the
powder was totally dissolved and ready for use in the following steps.
2. Fluorescent HA (HA-f) was prepared by (1) 0.39 g MES free acid
(2-(N-morpholino) ethanesulfonic acid, Calbiochem) and was dissolved in 100 ml dd water.
(2) Solution A: 65 mg fluroresceinamine powder, (isomer I, Fluka) was dissolved in 9 ml
95% EtOH solution and then stirred for 10 minutes under a condition that light was
prohibited. (3) Solution B: 359 mg EDC powder (N-(3-Dimethylamino propyl)-N-ethyl
carbodiimide hydrochloride, Sigma) was dissolved in 9 ml MES buffer and then stirred for
minutes. (4) Solution C: 216 mg NHS powder (N-Hydroxysuccinimde, Sigma) was
dissolved in 9 ml MES buffer and then stirred for 10 minutes. (5) 3 ml Solution A was
slowly dropped into 50 ml 0.5% HA solution and then stirred for 10 minutes under a
condition that light was prohibited. (6) 3 ml Solution B and 5 ml Solution C were separately
dropped into the solution of step (5) and then stirred for 10 minutes under a condition that
light was prohibited. (7) 0.02 M MES buffer was slowly added into the solution of step (6)
until the volume reached 100 ml and then stirred for 24 hours at room temperature under a
condition that light was prohibited. (8) The product after reaction was poured into a dialysis
tubing (MW: 12000~14000) in 5 L dd water as a dialysis solution and then stirred for 5 days
at 4°C under a condition that light was prohibited with dialysis solution being changed
every 12 hours until the dialysis solution had no fluorescence. (9) The liquid after dialysis
was allocated into 50 c.c. plastic centrifuge tubes and then reserved at -20℃ refrigerator
overnight followed by drying in a freeze-drying machine under a condition that light was
prohibited. (10) The dried HA-f powder was reserved at -20℃ refrigerator. (11) 50 mg
HA-f powder was slowly added into 10 ml PBS buffer and then stirred for 6 hours until the
powder was totally dissolved.
3. Colon tissue of SD-rat (Sprague-Dawley Rat) aged 7-8 weeks was cut by scalpel
and then washed by PBS buffer followed by being cut to 3-4 cm long with soaking in PBS
buffer finally.
4. Injured colon tissue was prepared by brushing by toothbrush for 20 times
longitudinally and then soaking in PBS buffer.
5. Normal and injured colon tissues were put into a 12-well plate and then 1 ml 0.5
% HA-f solution was added into each well and shaken for 2 hours at room temperature.
Surplus HA-f solution was sucked by tip 2 hours later, and then soaked into PBS buffer for
minutes followed by removing PBS buffer repeatedly for 3 times.
6. Cleaned colon tissue was placed in a 12-well plate with lining tissue upwards and
then placed onto the dock of the IVIS (in vivo image system, XENOGEN). The default
parameter was set up as GFP (green fluorescent protein) whereas the excitation was 465 nm
and the emission was 500 nm and then the image was captured by software.
7. All values in the table are expressed as means of n observations. The histological
index was analyzed by Student’s t-test.
Result: The fluorescent index was quantified and arranged as in Fig. 4. The
fluorescent index of normal colon tissue was defined as 1. The other colon tissues tests were
calibrated by the defined value. The result showed that the HAs with the same average Mw
were absorbed in the injured colon tissues obviously higher than in the normal colon tissues
(P<0.01). In comparing the difference between HAs of three different average molecular
weights absorbed in the injured colon tissues, the fluorescent index of absorption of 350
KDa HA by the injured colon tissues was obviously higher than HAs of the other two
average molecular weights (2 MDa and 1 MDa). Further, the fluorescent index of absorption
of 1 MDa HA by even normal or injured colon tissues was higher than 2MDa HA.
Example 4: The body weight change of rat with or without administration of
HA aimed at colitis
Procedure:
1. Test purpose: to induce the colitis in the SPF grade SD (Sprague-Dawley) rats
with the TNBS in order to evaluate the effect for treating or preventing colitis by two kinds
of mixing HAs differing in weight proportion.
2. Test objective: IBD98, comprising LMWHA and HMWHA, whereas the
HMWHA was 2 million Da and the LMWHA was 350 kilo Da, mixed in the ratio of 8:2 and
1:1 by weight which were categorized into group A and group B, respectively, and dissolved
in PBS solution to produce a concentration of 0.125% (w/v).
3. Method: (1) Test target: Rats aged 8 weeks were selected, and classified into three
groups: group A represented mixing ratio of 8:2; group B represented mixing ratio of 1:1;
group C was treated by PBS instead of HA. (2) Animal test: all rats of the treating group
were fasted for 2 days; in test day 1, the rats were anesthetized for administrating 1 ml of
TNBS (50 mg/mL) via the rectum; through test days 4 to 14, administering 1 ml of two
categories of IBD98 via the rectum in groups A and B; in test day 9, the body weight
changes of half rats in groups A and B were observed. And the body weight changes of the
other half rats were observed in day 14. All rats of the control group were fasted for 2 days;
in test day 1, the rats were anesthetized for administrating 1 ml of TNBS (50 mg/mL) via
the rectum; in test days 4 to 14, administering 1 ml of PBS via the rectum; in test day 9, the
body weight changes of half rats in group C were observed. And the body weight changes of
the other half rats were observed in day 14.
Result:
1. Inflammatory index: the present disclosure used changes of average body weight
as an index to view the amelioration of colitis (IBD). The change of the body weight is a
convenient and direct index to check the treatment result.
2. The trend showed groups A and B both had relief effects on colitis which also
represented IBD through day 1 to day 14 (Figs. 5A and 5B). In average weight changes
between control and HAs, treatment effect of colitis caused the average body weights of
group by administered HAs to be kept higher than those of control group during the whole
experimental period even till test day 14 (Fig. 5B).
Example 5: HA effect on allergic disease
Procedure:
1. Test purpose: to induce the allergic disease, herein rhinitis, in the SPF grade SD
(Sprague-Dawley) rats.
2. Test objective: IBD98, comprising LMWHA and HMWHA, whereas the average
molecular weight of HMWHA is 2 million Da and the average molecular weight of
LMWHA is 350 kilo Da, mixed in the ratio of 1:1 by weight dissolved in PBS solution to
produce a HA solution at a concentration of 0.125% (w/v).
3. Method: (1) Test target: Nine rats aged 8 weeks were selected, and classified into
two groups randomly: Control group (PBS) consisted of 4 rats and the test group (HA)
consisted of 5 rats. (2) Animal test: during test day 1 to day 7, the rats were
intra-peritoneally (IP) injected with physiological saline containing ovalbumin (1 mg) and
alum (10 mg) in each day; just observing through test day 8 to day 13; during test day 14 to
day 27, dripping ovalbumin in saline solution (10μg/10μl/nostril) into bilateral nasal
cavities by micropipette. The effect of HA on the nasal symptoms after antigen challenge
were evaluated with rats on day 28 (D28) and day 30 (D30) after general sensitization.
Before 1 hour of the instillation of ovalbumin, the animals were dripped with the HA
solution or PBS (25 μL/nostril). After nasal instillation of ovalbumin in saline (10 μg/10
μL/nostril) into the bilateral nasal cavities, the animals were placed in the observation cage
(1 animal/ cage), and nasal rubbing were counted for 30 minutes. The nasal rubbing
frequency was calculated as the times of nasal rubbing per 30 minutes.
Result:
1. Allergic amelioration index: the present disclosure used the nose rubbing
frequency as an index of allergic amelioration.
2. The effect of the HA sample on the antigen-induced nasal symptoms were shown
in Fig. 6. The average nasal rubbing frequency induced by ovalbumin was 56.25±16.1
times/ 30 minutes on day 28 (D28) and 70.0±41.3 times/ 30 minutes on day 30 (D30).
Compared with the control group, nasal rubbing was reduced significantly by the HA
solution on day 28 and obviously reduced on day 30.
The term ‘comprising’ as used in this specification and claims means ‘consisting at
least in part of’. When interpreting statements in this specification and claims which
includes the ‘comprising’, other features besides the features prefaced by this term in each
statement can also be present. Related terms such as ‘comprise’ and ‘comprised’ are to be
interpreted in similar manner.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such documents, or such sources of information, in any jurisdiction, are prior art, or form
part of the common general knowledge in the art.
Claims (15)
1. Use of a hyaluronic acid mixture including a low average molecular weight hyaluronic acid (LMWHA) and a high average molecular weight hyaluronic acid 5 (HMWHA), wherein the average molecular weight (Mw) of LMWHA is between 50 kilo Da and 1.5 million Da, and the average Mw of HMWHA is between 1.5 million Da and 5 million Da, but 1.5 million Da is excluded from both the average molecular weights of the LMWHA and of the HMWHA, wherein the average Mw of LMWHA is apart from the average Mw of HMWHA by at least 0.5 million Da, and a mixing ratio of the LMWHA to 10 the HMWHA is in a range from 20:80 to 80:20 by weight; in the manufacture of a medicament for treating or preventing a respiratory mucosa related disorder or disease.
2. The use of claim 1 wherein the medicament comprises a therapeutically effective amount of the hyaluronic acid mixture.
3. The use of claim 1 or claim 2, wherein the respiratory mucosa related disorder or 15 disease comprises symptoms of inflammation, allergic reaction or bleeding.
4. The use of any one of claims 1 to 3, wherein the respiratory mucosa related disorder or disease is allergic rhinitis or bronchitis.
5. The use of any one of claims 1 to 4, wherein the medicament is formulated as a dosage form for respiratory tract use. 20
6. The use of any one of claims 1 to 4, wherein the medicament is formulated for administration as a spray or by inhalation.
7. The use of claim 4, wherein the medicament is formulated for administration with a drug selected from the group consisting of antihistamines, antiallergics, anticongestives, steroids or antiasthmatics.
8. The use of any one of claims 1 to 7, wherein the average Mw of LMWHA is between 0.1 million Da and 1.5 million Da.
9. The use of any one of claims 1 to 7, wherein the average Mw of LMWHA is between 0.1 million Da and 0.5 million Da. 5
10. The use of any one of claims 1 to 7, wherein the average Mw of HMWHA is between 1.5 million Da and 3.5 million Da.
11. The use of any one of claims 1 to 7, wherein the average Mw of HMWHA is between 1.5 million Da and 2.5 million Da.
12. The use of any one of claims 1 to 7, wherein the mixing ratio of the LMWHA to 10 HMWHA is 1:1 by weight.
13. The use of any one of claims 2 to 7, wherein the therapeutically effective amount is at a range from 0.05 mg/ml to 50 mg/ml.
14. The use of claim 13, wherein the therapeutically effective amount is at a range from 0.05 mg/ml to 5 mg/ml. 15
15. A use of any one of claims 1 to 14 substantially as herein described with reference to any example thereof and with or without reference to the accompanying figures.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11173628.6A EP2545925B1 (en) | 2011-07-12 | 2011-07-12 | Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases |
EP11173628.6 | 2011-07-12 | ||
PCT/US2012/045259 WO2013009519A2 (en) | 2011-07-12 | 2012-07-02 | Materials for treating and preventing mucosa related disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613779A NZ613779A (en) | 2015-07-31 |
NZ613779B2 true NZ613779B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10709731B2 (en) | Materials for treating and preventing mucosa related disease | |
US10471151B2 (en) | Composition for use in treating and preventing inflammation related disorder | |
TWI516285B (en) | Pharmaceutical formulation containing glycosaminoglycan | |
TWI446915B (en) | Composition for use in treating and preventing mucosa related disease | |
US20120157408A1 (en) | Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer | |
NZ613779B2 (en) | Materials for treating and preventing mucosa related disease | |
US20160193343A1 (en) | Composition for use in treating and preventing inflammation related disorder | |
US20160008474A1 (en) | Pharmaceutical formulation containing glycosaminoglycan | |
NZ611857B2 (en) | Composition for use in treating and preventing inflammation related disorder | |
KR20010108036A (en) | Preventive for respiratory infectious diseases |